Standard BioTools Inc. $LAB Holdings Boosted by Casdin Capital LLC

Casdin Capital LLC increased its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 14.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,783,856 shares of the company’s stock after buying an additional 11,225,000 shares during the quarter. Standard BioTools accounts for about 7.1% of Casdin Capital LLC’s investment portfolio, making the stock its 4th largest position. Casdin Capital LLC owned approximately 23.09% of Standard BioTools worth $113,643,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in LAB. Mak Capital One LLC boosted its holdings in shares of Standard BioTools by 184.6% in the third quarter. Mak Capital One LLC now owns 15,931,806 shares of the company’s stock worth $20,711,000 after buying an additional 10,334,384 shares during the last quarter. Long Focus Capital Management LLC boosted its holdings in shares of Standard BioTools by 12.8% in the third quarter. Long Focus Capital Management LLC now owns 11,362,804 shares of the company’s stock worth $14,772,000 after buying an additional 1,292,804 shares during the last quarter. Kent Lake PR LLC purchased a new position in shares of Standard BioTools in the second quarter worth approximately $1,200,000. Landscape Capital Management L.L.C. purchased a new position in shares of Standard BioTools in the fourth quarter worth approximately $792,000. Finally, AQR Capital Management LLC boosted its holdings in shares of Standard BioTools by 862.2% in the first quarter. AQR Capital Management LLC now owns 482,912 shares of the company’s stock worth $522,000 after buying an additional 432,725 shares during the last quarter. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on LAB. Weiss Ratings downgraded shares of Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 27th. Wall Street Zen upgraded shares of Standard BioTools from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $1.35.

Standard BioTools Trading Down 2.6%

NASDAQ LAB opened at $0.81 on Thursday. Standard BioTools Inc. has a 12 month low of $0.79 and a 12 month high of $1.72. The stock has a market cap of $316.24 million, a price-to-earnings ratio of 4.05 and a beta of 1.39. The company’s 50 day moving average is $0.98 and its two-hundred day moving average is $1.16.

Standard BioTools Company Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.